Apricus Biosciences Announces Sale of Ex-U.S. Vitaros Assets and Rights to Ferring Pharmaceuticals
Apricus Expects to Receive Approximately $12.7 Million from Ferring
Apricus to Focus on Vitaros U.S. NDA Re-Submission and Pipeline Assets Post-Closing
SAN DIEGO, March 08, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that it completed the sale to Ferring International Center S.A. (“Ferring”) of Apricus’ ex-U.S. assets and rights related to Vitaros®, Apricus’ on-demand topical cream indicated for the treatment of patients with erectile dysfunction pursuant to a definitive agreement with Ferring. Ferring is Apricus’ existing commercialization partner for Vitaros in Latin America and certain parts of Europe and Asia. Apricus will retain its Vitaros rights in the U.S. and it remains on track to re-submit the Vitaros NDA to the FDA in the third quarter of 2017.
“This transaction reflects the continued execution of our corporate strategy of developing, obtaining regulatory approval for, and partnering novel topical prescription treatments in areas of significant unmet need,” said Richard Pascoe, Chief Executive Officer of Apricus. “Moreover, this transaction will allow us to focus our financial resources on obtaining U.S regulatory approval for Vitaros, accelerate the advancement of our clinical pipeline, strengthen our balance sheet with non-dilutive capital, extinguish our existing debt facility, eliminate certain future ex-U.S. Vitaros liabilities and lower our quarterly operating expenses by approximately 30%. I want to thank all of our commercial partners, including Ferring, for their commitment to making Vitaros a successful global brand. We look forward to their continued success as we work towards a U.S. Vitaros NDA re-submission in the third quarter of this year.”
Associated with the acquisition of the ex-U.S. assets and rights related to Vitaros, Ferring has agreed to pay Apricus an upfront payment of $11.5 million, due upon closing, and up to an additional $700,000 with respect to certain product inventory. Furthermore, the parties have entered into a transition services agreement, whereby Ferring has agreed to pay Apricus an amount equal to $500,000, payable over two calendar quarters, in exchange for Apricus’ assistance in facilitating the transfer of such assets and know-how to Ferring, subject to certain limitations. Ferring will be responsible for managing all Vitaros-related activities outside the U.S. at its cost and working with existing Vitaros commercialization partners outside the United States.
About Ferring Pharmaceuticals
Headquartered in Saint-Prex, Switzerland, Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group active in global markets. The company identifies, develops and markets innovative products in the areas of reproductive health, urology, gastroenterology, endocrinology and orthopedics. Ferring has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries.
For further information on Ferring or its products, visit www.ferring.com.
About Apricus Biosciences, Inc.
Apricus Biosciences, Inc. (APRI) is a biopharmaceutical company advancing innovative medicines in urology and rheumatology. Apricus has two product candidates currently in development. Vitaros is a product candidate in the United States for the treatment of erectile dysfunction, which is in-licensed from Warner Chilcott Company, Inc., now a subsidiary of Allergan plc (Allergan). RayVa is our product candidate in Phase 2 development for the treatment of the circulatory disorder Raynaud’s phenomenon, secondary to scleroderma, for which we own worldwide rights.
For further information on Apricus, visit http://www.apricusbio.com.
Vitaros™ is Apricus’ trademark in the United States, which is pending registration and subject to the agreement with Allergan. Vitaros® is a registered trademark of NexMed International Limited, and will be assigned to Ferring B.V. worldwide, excluding the United States. RayVa™ is Apricus’ trademark, which is registered in certain countries throughout the world and pending registration in the United States.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act, as amended. Statements in this report that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things: statements regarding the cash proceeds from the sale of the purchased assets and under the transition services agreement, the extinguishment of outstanding debt and Apricus’ plans to resubmit the Vitaros NDA. Actual results could differ from those projected in any forward-looking statements due to a variety of reasons that are outside of Apricus’ control, including, but not limited to: disruption of Apricus’ business and diversion of its management’s time and attention in order to provide transition services under the transition services agreement; Apricus not realizing the full economic benefit from the transaction, including as a result of indemnification claims under the asset purchase agreement and the retention by Apricus’ of certain liabilities associated with the product business; long-term financial risks associated with selling Apricus’ commercialized and registered products; risks related to Apricus’ planned resubmission of the Vitaros NDA; and other risks detailed in Apricus’ public periodic filings with the SEC. These forward-looking statements are made as of the date of this press release, and the Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q, and other filings made with the SEC. Copies of these reports are available from the SEC's website at www.sec.gov or without charge from the Company.
The Trout Group
Om Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
+1 212 401 8700http://www.nasdaqomx.com
NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra Nasdaq GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Nasdaq GlobeNewswire
LexinFintech Holdings Ltd. Reports Fourth Quarter and Full Year 2017 Unaudited Financial Results20.3.2018 12:22 | Pressemelding
SHENZHEN, China, March 20, 2018 (GLOBE NEWSWIRE) -- LexinFintech Holdings Ltd. ("Lexin" or the "Company") (NASDAQ:LX), a leading online consumer finance platform for educated young adults in China, today announced its unaudited financial results for the fourth quarter and full year ended December 31, 2017. Fourth Quarter and Full Year 2017 Operational Highlights: Total loan originations in 2017 reached RMB47.7 billion, representing an increase of 115% from RMB22.2 billion in 2016. Total outstanding principal balance of loans reached RMB19.3 billion as of December 31, 2017, representing an increase of 94.7% from RMB9.9 billion as of December 31, 2016. The weighted average tenor of loans originated on our platform in 2017 was approximately 9.53 months. The effective APR1 was 22.8% for the fourth quarter of 2017. Customer acquisition cost2 amounted to RMB99 in 2017, representing a decrease of 22% from 127 in 2016. Total number of registered users reached 23.9 million as of December 31, 20
Merus and the Vall d'Hebron Institute of Oncology Announce Research Collaboration to Develop Innovative Bispecific Antibodies for Therapeutic Applications in the Treatment of Cancer20.3.2018 12:00 | Pressemelding
UTRECHT, The Netherlands, March 20, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), and the Vall d'Hebron Institute of Oncology (VHIO), a leading comprehensive cancer center of excellence located in Barcelona, Spain, today announced a strategic research collaboration to develop novel agents for therapeutic applications. The collaboration will combine Merus' proprietary Biclonics® technology platform and VHIO's expertise in clinical, translational and preclinical research. Josep Tabernero, M.D., Ph.D., M.Sc., Director of VHIO, has served as a scientific advisor to Merus for the past six years. "VHIO is an internationally renowned leader in cancer research. This new collaboration builds on the successful working relationship established in the Phase 1/2 study for MCLA-128, a Biclonics® targeting HER3 signaling, and in the preclinical evaluation of MCLA-158, a Biclonics® target
NIH/NCI Grants Awarded to Inspirata and Case Western Reserve University Projects to Investigate Whole Slide Image Analysis to Predict the Aggressiveness of Certain Cancers20.3.2018 11:13 | Pressemelding
Multiple academic/industry grants and other funding totaling nearly $10M are being used to develop and validate digital pathology image-based risk predictors for breast, lung and head/neck cancers. If validated, the predictors will help identify which patients have a greater probability of cancer recurrence and a greater need for chemotherapy. Vancouver, BC, March 20, 2018 (GLOBE NEWSWIRE) -- Cancer informatics and digital pathology workflow solution provider Inspirata®, Inc. announced today that it has been awarded a new National Institute of Health/National Cancer Institute (NIH/NCI) R01 grant with its academic partner, Case Western Reserve University (CWRU) in Cleveland, Ohio. This grant will enable the multidisciplinary team of cancer researchers and physicians to develop and validate an image-based risk predictor of aggressiveness in head & neck cancers based on digitized H&E stained pathology images alone. This 5-year $3.15M Academic Industry Partnership (AIP) R01 grant is in add
Auth0 Announces Key Distribution Partnership with AppXite20.3.2018 10:00 | Pressemelding
End-to-end identity management now available to all AppXite resellers LONDON, March 20, 2018 (GLOBE NEWSWIRE) -- Auth0, a global leader in Identity-as-a-Service (IDaaS), has announced a new partnership with AppXite, a global leader in SaaS solutions aggregation and fully owned subsidiary of Atea. Auth0's identity and access management platform will be added to AppXite's SaaS offering, adding even more value to its global reseller offering. Auth0's Universal Identity platform will now be accessible to AppXite's extensive global network of managed service providers (MSPs), value-added resellers (VARs), and systems integrators (SIs) around the world. AppXite's reseller network can integrate Auth0's identity platform into their own offering to increase profitability, expand market share, and help their customers thrive in today's cloud economy. "Over the past few years, we have noticed a marked increase in demand for identity management. Companies are realizing the complexity of trying to
McDonald's Becomes the First Restaurant Company to Set Approved Science Based Target to Reduce Greenhouse Gas Emissions20.3.2018 09:03 | Pressemelding
Company Expected to Prevent 150 Million Metric Tons of Emissions by 2030 OAK BROOK, Ill., March 20, 2018 (GLOBE NEWSWIRE) -- Today, McDonald's announces it will partner with franchisees and suppliers to reduce greenhouse gas emissions related to McDonald's restaurants and offices by 36% by 2030 from a 2015 base year in a new strategy to address global climate change. Additionally, McDonald's commits to a 31% reduction in emissions intensity (per metric ton of food and packaging) across its supply chain by 2030 from 2015 levels. This combined target has been approved by the Science Based Targets initiative(SBTi). Through these actions, McDonald's expects to prevent 150 million metric tons of greenhouse gas emissions from being released into the atmosphere by 2030. This is the equivalent of taking 32 million passenger cars off the road for an entire year or planting 3.8 billion trees and growing them for 10 years. The target will enable McDonald's to grow as a business without growing it
Nitinat Provides Update on the Carscallen Gold Property19.3.2018 21:30 | Pressemelding
TORONTO, March 19, 2018 (GLOBE NEWSWIRE) -- Further to its press release dated March 12, 2018 whereby Nitinat Minerals Corp. (the "Corporation") (TSX-V:NZZ) (Frankfurt:04U1) announced its option to acquire four (4) additional claims (collectively, the "Claims") abutting the western boundaries of the Corporation's current mining claims in Carscallen Township, Ontario (the "Carscallen Gold Property"), the Corporation is pleased to provide additional information pertaining to the Claims. The Corporation intends to implement an exploration program for the Claims to fully explore the potential of the Claims. The "preliminary technical appraisal" provided herein, along with the geophysics that the Corporation intends to undertake, will identify potential drill targets. The property encompassing the Claims is of particular interest in that surface exploration to date on the Claims has shown the existence of historic surface mining and sampling. The Corporation is currently assessing the most
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom